Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2006
Business Overview: The Company operates two primary business units: CooperVision (CVI), which markets and manufactures contact lenses, and CooperSurgical (CSI), which produces medical devices and surgical instruments for gynecologists and obstetricians. The reporting period includes the full impact of the Ocular Sciences, Inc. acquisition completed in January 2005, as well as two smaller acquisitions in November 2005 (Inlet Medical and NeoSurg Technologies).
Key Financial Metrics
| Metric (in thousands) | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $205,739 | $147,550 |
| Gross Profit | $129,161 | $92,118 |
| Gross Margin | 63% | 62% |
| Operating Income | $33,714 | $26,617 |
| Net Income | $17,954 | $17,709 |
| Diluted EPS | $0.39 | $0.46 |
| Operating Cash Flow | $33,054 | $35,807 |
| Total Debt | $765,771 | $704,912 |
| Cash and Equivalents | $24,597 | $30,826 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 39% year-over-year, driven primarily by CooperVision (up 45%) due to the inclusion of Ocular Sciences and strong growth in specialty lenses. CooperSurgical sales grew 14%.
- Earnings Per Share: Diluted EPS decreased from $0.46 to $0.39. This decline was caused by a 21% increase in the weighted average number of shares outstanding (due to the Ocular acquisition) and the adoption of SFAS 123R, which reduced net income by $3.5 million due to new stock-based compensation expense recognition.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 40% to $84.4 million, largely due to stock option expenses ($4.8 million) and acquisition-related costs. Research and development expenses more than doubled to $5.9 million.
- Debt Structure: Total debt increased to approximately $766 million. The Company amended its credit facility in December 2005, refinancing prior loans and increasing the revolving credit facility to $500 million. Interest expense increased 131% to $8.4 million, partly due to the full quarter of interest on Ocular-related debt compared to only one month in the prior year.
- Tax Rate: The effective tax rate dropped to 11% from 21% in the prior year, reflecting a shift of business to jurisdictions with lower tax rates.
Guidance, Outlook, and Risks
- Outlook: Management expects capital expenditures for fiscal 2006 to range between $150 million and $160 million, with 70% allocated to expanded manufacturing capacity. The Company anticipates funding operations, dividends, and smaller acquisitions through existing cash and operating cash flows.
- Product Strategy: CooperVision is expanding manufacturing capacity for silicone hydrogel lenses, with a planned U.S. launch in the second half of calendar 2006. The Company is also integrating the Ocular acquisition to optimize operational synergies, with total restructuring costs estimated at $25–$30 million.
- Legal Proceedings:
- Securities Class Action: A lawsuit filed in February 2006 alleges improper accounting for the Ocular merger, inflated earnings guidance, and unrealistic synergy claims. The Company intends to vigorously defend the suit.
- Patent Litigation: Bausch & Lomb alleges infringement regarding Biomedics toric soft contact lenses. The Company believes the lawsuit is without merit.
- Tax Litigation: The IRS has asserted a deficiency of approximately $44.8 million in taxes plus penalties for Ocular for the years 1999–2001. The Company is contesting this in the U.S. Tax Court.
- Internal Controls: Management identified a material weakness in internal controls regarding accounting for acquisitions in the prior fiscal year. Remediation steps, including improved training and review procedures, were implemented during the quarter.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the long-term impact of SFAS 123R adoption on future earnings, as $4.9 million in expense was recognized in this quarter alone.
- Acquisition Integration: Monitor the realization of synergies from the Ocular Sciences acquisition and the integration of Inlet and NeoSurg, specifically regarding the $25–$30 million restructuring cost estimate.
- Debt Covenants: Review compliance with the amended credit facility covenants, specifically the leverage ratio (currently 3.088 to 1) and the requirement to reduce it to 3.0 to 1 by October 2006.
- Legal Contingencies: Assess the potential financial exposure from the securities class action lawsuit and the IRS tax deficiency claim, which could materially affect future cash flows.
- Inventory Levels: Note that inventory months on hand increased to 7.8 months (from 6.8) in anticipation of new product launches; monitor for potential obsolescence risks if sales do not meet expectations.